Sanofi (NASDAQ:SNY) Shares Bought by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA grew its holdings in shares of Sanofi (NASDAQ:SNY) by 8.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 141,159 shares of the company’s stock after purchasing an additional 10,941 shares during the period. Massachusetts Financial Services Co. MA’s holdings in Sanofi were worth $6,849,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Envestnet Asset Management Inc. lifted its position in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after purchasing an additional 246,224 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in shares of Sanofi by 11.9% in the second quarter. Oppenheimer Asset Management Inc. now owns 135,751 shares of the company’s stock valued at $6,587,000 after buying an additional 14,455 shares during the period. Wrapmanager Inc. boosted its stake in Sanofi by 18.1% during the second quarter. Wrapmanager Inc. now owns 8,543 shares of the company’s stock valued at $415,000 after buying an additional 1,310 shares in the last quarter. Parallel Advisors LLC grew its holdings in Sanofi by 14.6% during the second quarter. Parallel Advisors LLC now owns 7,732 shares of the company’s stock worth $375,000 after acquiring an additional 987 shares during the period. Finally, HBK Sorce Advisory LLC bought a new stake in Sanofi in the second quarter worth about $208,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $57.63 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The company has a market cap of $145.96 billion, a P/E ratio of 28.96, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The firm’s 50 day simple moving average is $54.34 and its 200-day simple moving average is $50.48.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The company’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.95 EPS. As a group, equities research analysts predict that Sanofi will post 4.25 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on SNY shares. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.